MOORE CAPITAL MANAGEMENT, LP - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.

Quarter-by-quarter ownership
MOORE CAPITAL MANAGEMENT, LP ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2022$2,228,500
+164.4%
50,000
+66.7%
0.05%
+165.0%
Q3 2022$843,000
+76.0%
29,993
+68.7%
0.02%
+53.8%
Q2 2022$479,000
-21.0%
17,7810.0%0.01%
-13.3%
Q1 2022$606,000
-63.6%
17,781
-81.3%
0.02%
-16.7%
Q4 2020$1,664,00095,0000.02%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2021
NameSharesValueWeighting ↓
Kynam Capital Management, LP 1,605,390$71,552,23210.98%
Octagon Capital Advisors LP 761,398$33,935,5095.28%
TSP Capital Management Group, LLC 269,895$12,029,2254.50%
Redmile Group, LLC 1,977,451$88,134,9913.60%
COMMODORE CAPITAL LP 495,823$22,0993.33%
Tri Locum Partners LP 176,109$7,849,0003.18%
ACUTA CAPITAL PARTNERS, LLC 115,000$5,125,5503.15%
Ikarian Capital, LLC 267,476$11,921,4062.88%
RTW INVESTMENTS, LP 3,084,215$137,463,4632.81%
Eversept Partners, LP 558,774$24,904,5572.18%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders